CLAIMS

1. Use of a~~A~~ therapeutic agent in the manufacture of a medicament for the treatment of nerve damage in a patient,

the therapeutic agent being ~~an intravenously administered~~ a formulation comprising mesenchymal stem cells and/or cells capable of differentiating into mesenchymal stem cells,

wherein the therapeutic agent is to be intravenously administered to the patient; and wherein the therapeutic agent ~~being~~ is to be administered to the~~a~~ patient in combination with the stimulation of a nerve of the patient;~~,~~ and

wherein the stimulation ~~being~~ of the nerve of the patient is to be ~~performed~~applied during a period from before to 6 hours after the administration of the therapeutic agent.

2. Use of a~~A~~ therapeutic agent in the manufacture of a medicament for the treatment of nerve damage in a patient,

the therapeutic agent being ~~an intravenously administered~~ a formulation comprising mesenchymal stem cells and/or cells capable of differentiating into mesenchymal stem cells,

wherein the therapeutic agent is to be intravenously administered to the patient; and wherein the therapeutic agent ~~being~~ is to be administered to the~~a~~ patient in combination with the stimulation of a nerve of the patient;~~,~~ and

wherein the stimulation ~~being~~ of the nerve of the patient is to be ~~preferentially~~ applied to at least one area selected from the group consisting of : an area of nerve damage, an

area near an area of nerve damage, and an area capable of compensating for a function of an area of nerve damage.

3. The ~~therapeutic agent~~ use according to claim 1 or 2, wherein the stimulation to be applied is at least one selected from the group consisting of : motor stimulation, sensory stimulation, electrical stimulation, magnetic stimulation, language stimulation, and higher brain function stimulation.